> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CeleCor Completes NDA Submission for Heart Attack Drug
- URL: https://www.fdaweb.com/celecor-completes-nda-submission-for-heart-attack-drug/
- Published: 2026-06-25T12:00:00.000Z
- Updated: 2026-09-14T13:41:56.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161379

CeleCor Therapeutics says it has submitted an NDA for Disaggpro (zalunfiban), an investigational treatment for ST-segment elevation myocardial infarction (STEMI), the most severe form of heart attack. The filing marks the completion of a rolling NDA after FDA granted a Fast Track designation in January.

The company says the filing is supported by results from the Phase 3 CeleBrate trial, which were presented at the American Heart Association Scientific Sessions in November and later published in *NEJM Evidence*. The multinational study demonstrated that administration of zalunfiban at the first point of medical contact reduced the risk of severe heart damage and other serious complications in patients experiencing STEMI heart attacks, it says.

Specifically, the data showed that early administration of zalunfiban at the first point of medical contact — such as in the ambulance, at home, or in the emergency department — improved blood flow to the heart before patients underwent catheterization procedures. Treatment was associated with an approximately 21% reduction in the risk of a larger heart attack or a composite endpoint that included death, stroke, reinfarction, stent thrombosis, or heart failure.

Zalunfiban is described as a novel small-molecule inhibitor of the platelet glycoprotein IIb/IIIa receptor. The company says the drug was designed as a subcutaneous injection that can be administered rapidly before patients reach a hospital, with the goal of preventing clot progression and limiting cardiac damage while restoring blood flow to blocked coronary arteries.